IL160607A0 - Use of c2-substituted indan-1-one systems for preparing medicaments for the prophylaxis or treatment of obesity - Google Patents

Use of c2-substituted indan-1-one systems for preparing medicaments for the prophylaxis or treatment of obesity

Info

Publication number
IL160607A0
IL160607A0 IL16060702A IL16060702A IL160607A0 IL 160607 A0 IL160607 A0 IL 160607A0 IL 16060702 A IL16060702 A IL 16060702A IL 16060702 A IL16060702 A IL 16060702A IL 160607 A0 IL160607 A0 IL 160607A0
Authority
IL
Israel
Prior art keywords
prophylaxis
obesity
systems
treatment
preparing medicaments
Prior art date
Application number
IL16060702A
Other languages
English (en)
Original Assignee
Aventis Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Gmbh filed Critical Aventis Pharma Gmbh
Publication of IL160607A0 publication Critical patent/IL160607A0/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/2264Obesity-gene products, e.g. leptin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/095Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A61K31/10Sulfides; Sulfoxides; Sulfones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365Lactones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
IL16060702A 2001-08-31 2002-08-17 Use of c2-substituted indan-1-one systems for preparing medicaments for the prophylaxis or treatment of obesity IL160607A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10142668A DE10142668A1 (de) 2001-08-31 2001-08-31 Verwendung von C2-substituierten Indan-1-on-Systemen zur Herstellung von Medikamenten zur Prophylaxe oder Behandlung von Obesitas
PCT/EP2002/009208 WO2003020256A1 (de) 2001-08-31 2002-08-17 Verwendung von c2-substituierten indan-1-on-systemen zur herstellung von medikamenten zur prophylaxe oder behandlung von obesitas

Publications (1)

Publication Number Publication Date
IL160607A0 true IL160607A0 (en) 2004-07-25

Family

ID=7697238

Family Applications (2)

Application Number Title Priority Date Filing Date
IL16060702A IL160607A0 (en) 2001-08-31 2002-08-17 Use of c2-substituted indan-1-one systems for preparing medicaments for the prophylaxis or treatment of obesity
IL160607A IL160607A (en) 2001-08-31 2004-02-26 Use of c2-substituted indan-1-one systems for preparing medicaments for reduction of weight and for the prophylaxis or treatment of obesity

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL160607A IL160607A (en) 2001-08-31 2004-02-26 Use of c2-substituted indan-1-one systems for preparing medicaments for reduction of weight and for the prophylaxis or treatment of obesity

Country Status (10)

Country Link
US (1) US6946492B2 (es)
EP (1) EP1424999A1 (es)
JP (1) JP4342306B2 (es)
AU (1) AU2002336985B2 (es)
CA (1) CA2458555A1 (es)
DE (1) DE10142668A1 (es)
IL (2) IL160607A0 (es)
MX (1) MXPA04001853A (es)
PE (1) PE20030336A1 (es)
WO (1) WO2003020256A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010085811A2 (en) * 2009-01-26 2010-07-29 Taipei Medical University Use of pterosin compounds for treating diabetes and obesity
CN103333144B (zh) * 2013-06-17 2014-12-10 温州大学 一种2-硫基-3-卤代苯并呋喃化合物及其合成方法和用途

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0009554B1 (de) * 1978-07-27 1983-04-27 Schering Aktiengesellschaft Indanyl-Derivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende pharmazeutische Präparate
WO1989003681A1 (en) * 1987-10-19 1989-05-05 Pfizer Inc. Substituted tetralins, chromans and related compounds in the treatment of asthma
GB2322858A (en) * 1995-12-06 1998-09-09 Venantius Limited Indane dimer compounds with smooth muscle relaxing and/or mast cell stabilising and/or antiinflammatory activity
CA2241567A1 (en) 1996-01-17 1997-07-24 Novo Nordisk A/S Fused 1,2,4-thiadiazine and fused 1,4-thiazine derivatives, their preparation and use
HU227021B1 (en) 1996-08-30 2010-05-28 Novo Nordisk As Glp-1 derivatives
HUP0301101A3 (en) 1996-12-31 2009-03-30 Reddy S Res Foundation Novel heterocyclic compounds process for their preparation and pharmaceutical compositions containing them and their use in the treatment of diabetes and related diseases
JP2001510195A (ja) 1997-07-16 2001-07-31 ノボ ノルディスク アクティーゼルスカブ 縮合化1,2,4−チアジアジン誘導体、その調製及び使用
CZ20013117A3 (cs) * 1999-03-01 2002-06-12 Pfizer Products Inc. Oxamové kyseliny a jejich deriváty jako ligandy thyreoidního receptoru
FR2796070B1 (fr) * 1999-07-06 2003-02-21 Lipha Derives de benzodiazepines utilisables dans le traitement de dyslipidemies, de l'atherosclerose et du diabete, compositions pharmaceutiques les contenant et procedes de preparation
EP1078632A1 (en) 1999-08-16 2001-02-28 Sanofi-Synthelabo Use of monoamine oxydase inhibitors for the manufacture of drugs intended for the treatment of obesity

Also Published As

Publication number Publication date
US20030134882A1 (en) 2003-07-17
PE20030336A1 (es) 2003-05-19
IL160607A (en) 2011-03-31
CA2458555A1 (en) 2003-03-13
DE10142668A1 (de) 2003-03-20
AU2002336985B2 (en) 2006-11-16
WO2003020256A1 (de) 2003-03-13
JP4342306B2 (ja) 2009-10-14
MXPA04001853A (es) 2004-06-15
US6946492B2 (en) 2005-09-20
JP2005503396A (ja) 2005-02-03
EP1424999A1 (de) 2004-06-09

Similar Documents

Publication Publication Date Title
IL159347A0 (en) Arylamines for the treatment of conditions associated with gsk-3
IL160187A0 (en) Aerosolized decongestants for the treatment of sinusitis
HUP0401514A3 (en) Pharmaceutical compositions for the treatment of asthma
AU2003299791A1 (en) Substituted 3,5-dihydro-4h-imidazol-4-ones for the treatment of obesity
EP1534074A4 (en) POLYTHERAPY FOR THE TREATMENT OF OBESITY
IL159344A0 (en) Quinuclidines-substituted-multicyclic-heteroaryls for the treatment of disease
AU2002360251A8 (en) Medical devices comprising nanocomposites
IL196301A0 (en) Medicament for the treatment of hapatitis c
IL160524A0 (en) Imidazole-4-carboxamide derivatives, preparation and use thereof for treatment of obesity
AU2002310325A1 (en) Use of ozone for the prevention of infection caused by medical devices
IL161041A0 (en) Mch antagonists for the treatment of obesity
EP1384493A4 (en) IRRADIATOR
EP1390029A4 (en) PHENYLINDOLES FOR THE TREATMENT OF HIV INFECTION
AU2002342613A8 (en) Treatment for wounds
IL178903A0 (en) Medicaments containing n-sulfamoyl-n'-arylpiperazines for the prophylaxis or treatment of obesity and related conditions
AU2003263760A1 (en) Methods for the treatment or prevention of obesity
IL157145A0 (en) Use of dc23 antagonists for the treatment of neoplastic disorders
IL160600A0 (en) Use of polysubstituted indan-1-ol systems for the preparation of medicaments for the prophylaxis or treatment of obesity
AU2002364171A8 (en) Materials and methods for the treatment or prevention of obesity
HK1062810A1 (en) Use of il-18 inhibitors for the manufacture of medicaments for treatment and/or prevention of heartdisease
AU2002333447A1 (en) Use of polysubstituted indan-1-ol systems for producing drugs in the prophylaxis or treatment of obesity
AU2002236781A1 (en) Treatment for snoring
IL160607A0 (en) Use of c2-substituted indan-1-one systems for preparing medicaments for the prophylaxis or treatment of obesity
AU2002336984A1 (en) Use of C2-substituted Indane-1-ol systems for producing medicaments for the prophylaxis or treatment of obesity
AU2002342615A1 (en) Use of derivatives of C2-substituted indan-1-ol systems for producing medicaments for the prophylaxis or the treatment of obesity

Legal Events

Date Code Title Description
FF Patent granted